Liver elastography for risk-assessment of liver toxicity and risk factors for Sinusoidal obstruction syndrome in patients with acute lymphoblastic leukemia receiving inotuzumab ozogamicin - Summary - MDSpire

Liver elastography for risk-assessment of liver toxicity and risk factors for Sinusoidal obstruction syndrome in patients with acute lymphoblastic leukemia receiving inotuzumab ozogamicin

  • By

  • Jayastu Senapati

  • Elias Jabbour

  • Nicholas J. Short

  • Nitin Jain

  • Fadi Haddad

  • Tharakeswara Bathala

  • Iuliia Kovalenko

  • Aram Bidikian

  • Farhad Ravandi

  • Issa Khouri

  • Tapan M. Kadia

  • Rebecca Garris

  • Guillermo Montalban Bravo

  • Kelly Chien

  • Elizabeth Shpall

  • Partow Kebriaei

  • Hagop M. Kantarjian

  • August 7, 2024

  • 0 min

Share

Objective:

To evaluate the utility of baseline liver elastography in predicting liver toxicity and to identify risk factors for sinusoidal obstruction syndrome (SOS) in patients with B-cell acute lymphoblastic leukemia (B-cell ALL) treated with inotuzumab ozogamicin (InO), highlighting the clinical significance of these outcomes.

Key Findings:
  • 78% of patients had a median SWV < 1.7 m/s, indicating no significant liver fibrosis, which suggests a favorable liver health profile. Only 2% of patients developed SOS at a median follow-up of 22.4 months, indicating a low incidence of this serious complication. 10% of patients experienced ≥ grade 3 liver toxicity, all with baseline SWV < 1.7 m/s, underscoring the potential predictive value of elastography.
Interpretation:

Baseline liver elastography may help in assessing liver toxicity risk in patients treated with InO, but no significant risk factors for severe liver toxicity were identified, suggesting a need for further investigation.

Limitations:
  • Small sample size may limit generalizability of findings, and short follow-up duration may not capture long-term liver toxicity outcomes, alongside potential biases in patient selection.
Conclusion:

Liver elastography shows potential in predicting liver toxicity in B-cell ALL patients treated with InO, but further studies are needed to confirm these findings and explore risk factors for SOS, emphasizing the importance of ongoing research.

Original Source(s)

Liver elastography for risk-assessment of liver toxicity and risk factors for Sinusoidal obstruction syndrome in patients with acute lymphoblastic leukemia receiving inotuzumab ozogamicin

  • by Jayastu Senapati, Elias Jabbour, Nicholas J. Short, Nitin Jain, Fadi Haddad, Tharakeswara Bathala, Iuliia Kovalenko, Aram Bidikian, Farhad Ravandi, Issa Khouri, Tapan M. Kadia, Rebecca Garris, Guillermo Montalban Bravo, Kelly Chien, Elizabeth Shpall, Partow Kebriaei, Hagop M. Kantarjian

  • August 7, 2024

Related Content

Strategies for Organ Regeneration Using Cell Therapy

Hematological abnormalities in clinically diagnosed non-alcoholic steatohepatitis: prevalence, clinical correlates, and fibrosis risk in a case–control study from Qatar

The immunometabolic nature of MASH: framing immune cells within metabolic dysfunction